Ignite Creation Date:
2024-05-05 @ 5:09 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00392691
Status:
COMPLETED
Last Update Posted:
2019-05-15
First Post:
2006-10-25
Brief Title:
Melphalan Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkins Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Sponsor:
Organization:
Swiss Group for Clinical Cancer Research
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
20
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: